sCTLA-4, CD4+CD25+Foxp3+ regulatory T cells in Behçet's disease patients

dc.contributor.authorDemir, N.
dc.contributor.authorIlhan, F.
dc.contributor.authorDemir, T.
dc.contributor.authorGodekmerdan, A.
dc.date.accessioned2026-08-12T16:15:49Z
dc.date.issued2012
dc.departmentFırat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.endpageS117
dc.identifier.issn1593-098X
dc.identifier.issueSUPPL.72
dc.identifier.pmid23010434
dc.identifier.scopus2-s2.0-84873244312
dc.identifier.scopusqualityQ1
dc.identifier.startpageS116
dc.identifier.urihttps://hdl.handle.net/11508/43916
dc.identifier.volume30
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofClinical and Experimental Rheumatology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20260511
dc.subjectBehcet Syndrome; Biological Markers; Case-Control Studies; CD4 Lymphocyte Count; CTLA-4 Antigen; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Remission Induction; T-Lymphocytes, Regulatory; Treatment Outcome; azathioprine; CD4 antigen; colchicine; cyclosporin A; cytotoxic T lymphocyte antigen 4; interleukin 2 receptor alpha; prednisolone; salazosulfapyridine; transcription factor FOXP3; biological marker; CTLA4 protein, human; cytotoxic T lymphocyte antigen 4; forkhead transcription factor; FOXP3 protein, human; IL2RA protein, human; immunosuppressive agent; interleukin 2 receptor alpha; arthritis; Behcet disease; CD4+ CD25+ FoxP3+ T lymphocyte; CD4+ CD25+ T lymphocyte; cell count; cell function; cell loss; clinical article; controlled study; disease duration; human; letter; priority journal; protein blood level; protein expression; regulatory T lymphocyte; remission; urogenital ulcer; uveitis; blood; case control study; CD4 lymphocyte count; drug effect; immunology; metabolism; treatment outcome
dc.titlesCTLA-4, CD4+CD25+Foxp3+ regulatory T cells in Behçet's disease patients
dc.typeLetter

Dosyalar